The global pharma company whose name rhymes with the capital of China wants people to know that it is not in fact a Chinese ...

Bluebird reports 17 people with sickle cell disease started receiving Lyfgenia gene therapy, with 35 starting Zynteglo for ...

Merck KGaA reported a 16.6% decline in contract manufacturing due to an unrepeated Covid-19 contract, though overall life ...

Ascidian Therapeutics CEO Michael Ehlers is leaving the venture investor that serves as his home base and will join MPM ...

Sum­mit Ther­a­peu­tics and its Chi­nese part­ner Ake­so have a few com­peti­tors now.

The FDA has cleared PTC Ther­a­peu­tics’ gene ther­a­py for AADC de­fi­cien­cy, an ul­tra-rare dis­ease that im­pacts the ...

The GAO report highlights FDA's drug inspection program challenges, including 36% fewer inspections in 2023 compared to 2019 ...

The amylin field is heating up ahead of Novo Nordisk's much-anticipated CagriSema readout later this year. On Wednesday, ...

Johnson & Johnson is suing the federal government over HRSA's rejection of its proposed 340B drug discount model for Xarelto ...

Adaptimmune announced Wednesday that its experimental cell therapy based on T cell receptors shrank tumors by at least 30% in ...

TRexBio secured $84 million Series B funding, led by Delos Capital with Eli Lilly and Johnson & Johnson participating, to ...

Flagship Pioneering has appointed two new CEO-partners to advise its portfolio companies and help steer its spinouts Apriori ...